北京市2016年新确证未治疗HIV感染者传播性耐药突变研究

Surveillance of HIV transmitted drug resistance mutations in newly diagnosed treatment-naive patients in Beijing, 2016

目的分析北京市2016年新确证HIV感染者HIV病毒pol基因传播性耐药突变特征。方法利用一步法逆转录PCR和巢式PCR扩增感染者体内HIV病毒的pol基因，并对扩增产物进行测序。对得到的序列信息进行分析，分别获得病毒的亚型分布、耐药突变类型和构成。结果2016年北京市新确证HIV感染者传播性耐药突变比例为4．2％。712名感染者中，CRF01_AE亚型为主要流行亚型，占49．3％，CRF07_BC亚型占28．8％，B亚型占10．3％。结论与往年的研究相比，北京市未治疗的HIV感染者耐药率有所下降，总体上属于低水平的HIV耐药流行。

Objective The study aimed to get the prevalence of transmitted drug resistance mutations in newly diagnosed treatment-naive patients in beijing, 2016. Methods One-step RT PCR and Nested-PCR were used to amplify the pol gene. Through analysis of 712 pol sequences, the distribution of HIV subtype and the composition of HIV transmitted drug resistance mutations were obtained. Results The rate of HIV transmitted drug resistance mutations in Beijing is 4.2%. Among 712 patients, CRF01_AE was the predominant subtype, accounting for 49.3%, followed by CRF07_BC （28.8%） and subtype B （10.3%）. Conclusions We observed a decline in the prevalence of TDR resistance among newly diagnosed treatment-naive patients. Compared with previous study in Beijing, our study reveals a low-level prevalence of TDR in Beijing.